# Recombinant human serum albumin (rHSA)

Contract manufacturing (CMO/CDMO/toll) — Recombinant human serum albumin (rHSA) replaces plasma-derived HSA (pHSA) — constrained by donor-blood supply and viral-contamination risk since the 1940s — and the first rice-derived rHSA for injection has been approved by FDA/EMA/PMDA. The global rHSA market stands at USD 166 million.

Source: https://en.bioecon.ru/market/contract-manufacturing/recombinant-human-serum-albumin/